Regulus Therapeutics Inc. (RGLS) EPS Estimated At $-0.16; Five Prime Therapeutics (FPRX) Sentiment Is 1.34

April 17, 2018 - By Marie Mckinney

Regulus Therapeutics Inc. (NASDAQ:RGLS) Logo

Five Prime Therapeutics Inc (FPRX) investors sentiment increased to 1.34 in 2017 Q4. It’s up 0.30, from 1.04 in 2017Q3. The ratio has improved, as 67 hedge funds increased and opened new equity positions, while 50 cut down and sold their equity positions in Five Prime Therapeutics Inc. The hedge funds in our database now own: 25.47 million shares, up from 23.96 million shares in 2017Q3. Also, the number of hedge funds holding Five Prime Therapeutics Inc in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 21 Reduced: 29 Increased: 43 New Position: 24.

Analysts expect Regulus Therapeutics Inc. (NASDAQ:RGLS) to report $-0.16 EPS on May, 3.They anticipate $0.22 EPS change or 57.89% from last quarter’s $-0.38 EPS. After having $-0.14 EPS previously, Regulus Therapeutics Inc.’s analysts see 14.29% EPS growth. The stock decreased 0.67% or $0.004 during the last trading session, reaching $0.635. About 344,384 shares traded. Regulus Therapeutics Inc. (NASDAQ:RGLS) has declined 52.76% since April 17, 2017 and is downtrending. It has underperformed by 64.31% the S&P500.

Awm Investment Company Inc. holds 0.64% of its portfolio in Five Prime Therapeutics, Inc. for 150,000 shares. Bb Biotech Ag owns 827,500 shares or 0.51% of their US portfolio. Moreover, Rock Springs Capital Management Lp has 0.42% invested in the company for 425,000 shares. The Massachusetts-based Eventide Asset Management Llc has invested 0.36% in the stock. Granite Point Capital Management L.P., a Massachusetts-based fund reported 80,000 shares.

The stock increased 1.06% or $0.18 during the last trading session, reaching $17.24. About 71,591 shares traded. Five Prime Therapeutics, Inc. (FPRX) has declined 52.34% since April 17, 2017 and is downtrending. It has underperformed by 63.89% the S&P500.

Analysts await Five Prime Therapeutics, Inc. (NASDAQ:FPRX) to report earnings on May, 3. They expect $-0.54 EPS, up 55.37% or $0.67 from last year’s $-1.21 per share. After $-1.04 actual EPS reported by Five Prime Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -48.08% EPS growth.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the United States. The company has market cap of $605.41 million. The companyÂ’s product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. It currently has negative earnings. The Company’s product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors.

Among 9 analysts covering Regulus Therapeutics (NASDAQ:RGLS), 3 have Buy rating, 0 Sell and 6 Hold. Therefore 33% are positive. Regulus Therapeutics had 32 analyst reports since August 5, 2015 according to SRatingsIntel. On Tuesday, June 28 the stock rating was maintained by Needham with “Buy”. Chardan Capital Markets maintained the stock with “Buy” rating in Tuesday, June 7 report. The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) has “Buy” rating given on Tuesday, June 13 by Chardan Capital Markets. The firm earned “Hold” rating on Monday, June 12 by BMO Capital Markets. Wedbush maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) rating on Thursday, February 8. Wedbush has “Buy” rating and $4.0 target. The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) has “Buy” rating given on Tuesday, June 28 by Chardan Capital Markets. The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) earned “Buy” rating by Chardan Capital Markets on Wednesday, December 7. As per Wednesday, November 8, the company rating was maintained by BMO Capital Markets. The firm has “Market Perform” rating given on Tuesday, June 28 by BMO Capital Markets. The company was maintained on Wednesday, December 20 by Wedbush.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: